Novo Nordisk Launches Share Repurchase Program
Ticker: NONOF · Form: 6-K · Filed: Nov 25, 2024 · CIK: 353278
Sentiment: neutral
Topics: share-repurchase, capital-allocation, regulation
TL;DR
Novo Nordisk is buying back its own stock, signaling confidence.
AI Summary
Novo Nordisk A/S announced on November 25, 2024, that it initiated a share repurchase program on November 11, 2024. This program is being conducted in accordance with European regulations MAR and Commission Delegated Regulation (EU) 2016/1052.
Why It Matters
Share repurchases can signal management's confidence in the company's valuation and potentially boost earnings per share.
Risk Assessment
Risk Level: low — This is a routine corporate action related to capital allocation and does not inherently introduce new business risks.
Key Players & Entities
- Novo Nordisk A/S (company) — Registrant
- November 25, 2024 (date) — Announcement date
- November 11, 2024 (date) — Program initiation date
- Regulation No 596/2014 (regulation) — Governing regulation for share repurchase
- Commission Delegated Regulation (EU) 2016/1052 (regulation) — Governing regulation for share repurchase
FAQ
When did Novo Nordisk initiate its share repurchase program?
Novo Nordisk initiated its share repurchase program on November 11, 2024.
What is the purpose of this filing?
This filing is a Report of Foreign Private Issuer (Form 6-K) to announce the initiation of a share repurchase program.
Under which regulations is the share repurchase program being conducted?
The program is being conducted in accordance with Article 5 of Regulation No 596/2014 and Commission Delegated Regulation (EU) 2016/1052.
What is the company's official name as specified in its charter?
The company's exact name as specified in its charter is Novo Nordisk A/S.
Where is Novo Nordisk A/S's principal executive office located?
Novo Nordisk A/S's principal executive office is located at Novo Allé DK- 2880, Bagsvaerd Denmark.
Filing Stats: 618 words · 2 min read · ~2 pages · Grade level 10.3 · Accepted 2024-11-25 11:17:21
Filing Documents
- f6k_112524.htm (6-K) — 24KB
- logo.jpg (GRAPHIC) — 76KB
- ca.jpg (GRAPHIC) — 24KB
- 0001171843-24-006549.txt ( ) — 163KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf of the undersigned, thereunto duly authorized. Date: November 25, 2024 NOVO NORDISK A/S Lars Fruergaard Jørgensen Chief Executive Officer